July 8 (SeeNews) - Bulgarian veterinary drugs producer Biovet [BUL:53B] said that it will launch this year the construction of a new plant for vaccines at its production base in the town of Razgrad, in the northeast of the country.
Biovet will also continue the construction of its plant for pharmaceutical products and feed additives in the town of Peshtera, in south-central Bulgaria, the company said in a financial statement.
You can download the 2023 Agriculture industry in Southeast Europe report here
Earlier this year, the U.S. Department of Agriculture (USDA) said that it intends to grant Bulgaria's Huvepharma - the majority owner of Biovet - an exclusive royalty-bearing license for an experimental African swine fever vaccine.
Biovet has three production sites in Bulgaria - in the towns of Peshtera, Razgrad and Botevgrad.
Biovet generated sales of 285.5 million levs ($163.8 million/146.0 million euro) in 2018.
(1 euro = 1.95583 levs)